文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

非肾上腺素能血管升压药用于血管舒张性休克或围术期血管麻痹:随机对照试验的荟萃分析

Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials.
PubMed 文献 · Crit Care · 2024-12-30
一句话结论在脓毒性休克成人中,非肾上腺素能血管升压药与死亡率降低相关(RR 0.92,95%CI 0.86-0.97),但单一药物均未达统计学显著。

该系统评价与荟萃分析纳入51项随机对照试验共5715例成人患者,比较非肾上腺素能血管升压药(血管加压素、特利加压素、 selepressin、血管紧张素II、亚甲蓝、羟钴胺)与单独肾上腺素能血管升压药或安慰剂。主要终点为最长随访期死亡率。脓毒性休克亚组(30项研究)非肾上腺素能组死亡率显著降低(43% vs 48%;RR 0.92;95%CI 0.86-0.97;P=0.03;I²=0%),但单一药物均无显著生存获益。心脏手术(RR 0.82;95%CI 0.55-1.22;P=0.32)与非心脏手术(RR 0.66;95%CI 0.31-1.41;P=0.28)亚组无显著差异,置信区间包括无效和临床重要获益两种可能。作者认为这些发现支持进一步开展以去甲肾上腺素为基础常规治疗为对照的随机对照试验。

要点

  • 脓毒性休克患者:非肾上腺素能血管升压药组死亡率43%(960/2232) vs 肾上腺素能组48%(898/1890),RR 0.92(95%CI 0.86-0.97;P=0.03;I²=0%)。
  • 脓毒性休克亚组中,血管加压素、特利加压素、selepressin、血管紧张素II、亚甲蓝、羟钴胺各自的单独分析均未显示显著生存获益。
  • 心脏手术患者:非肾上腺素能组死亡率8.3%(34/410) vs 对照组11%(47/412),RR 0.82(95%CI 0.55-1.22;P=0.32;I²=12%),无显著差异。
  • 非心脏手术患者:非肾上腺素能组死亡率2.3%(9/388) vs 对照组4.7%(18/383),RR 0.66(95%CI 0.31-1.41;P=0.28;I²=0%),无显著差异。
  • 作者认为,心脏与非心脏手术亚组的置信区间包括无效和临床重要获益两种可能,支持进一步开展以去甲肾上腺素为基础常规治疗为对照的随机对照试验。

适用人群与场景

  • 接受血管升压药治疗的成人血管舒张性休克或围术期血管麻痹患者。
  • 纳入研究分为脓毒性休克(30项)、心脏手术(11项)和非心脏手术(10项)三类。

研究设计与关键结果

  • 研究类型:随机对照试验的系统评价与荟萃分析,共纳入51项随机对照试验、5715例患者;脓毒性休克30项、心脏手术11项、非心脏手术10项。
  • 干预与对照:非肾上腺素能血管升压药(血管加压素、特利加压素、selepressin、血管紧张素II、亚甲蓝、羟钴胺) vs 单独肾上腺素能血管升压药或安慰剂。
  • 主要终点(最长随访期死亡率)—脓毒性休克:非肾上腺素能组960/2232(43%) vs 肾上腺素能组898/1890(48%),RR 0.92(95%CI 0.86-0.97;P=0.03;I²=0%),非肾上腺素能组死亡率显著降低。
  • 脓毒性休克亚组中,单一非肾上腺素能血管升压药均未显示显著生存获益。
  • 主要终点—心脏手术:非肾上腺素能组34/410(8.3%) vs 对照组47/412(11%),RR 0.82(95%CI 0.55-1.22;P=0.32;I²=12%),无显著差异。
  • 主要终点—非心脏手术:非肾上腺素能组9/388(2.3%) vs 对照组18/383(4.7%),RR 0.66(95%CI 0.31-1.41;P=0.28;I²=0%),无显著差异。
  • 偏倚风险:Cochrane随机试验偏倚风险工具版本2判定17项研究为低偏倚风险。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与荟萃分析,方案在PROSPERO注册(CRD42024505039)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在脓毒性休克成人中,使用非肾上腺素能血管升压药与死亡率降低相关(RR 0.92;95%CI 0.86-0.97),但单一药物均未达统计学显著,作者认为需进一步开展以去甲肾上腺素为基础常规治疗为对照的随机对照试验。
  • 在心脏手术或非心脏手术患者中,非肾上腺素能血管升压药对生存的汇总效应未达统计学显著,置信区间包括无效和临床重要获益两种可能,作者据此认为值得进一步开展随机对照试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Excessive exposure to adrenergic vasopressors may be harmful. Non-adrenergic vasopressors may spare adrenergic agents and potentially improve outcomes. We aimed to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of non-adrenergic vasopressors in adult patients receiving vasopressor therapy for vasodilatory shock or perioperative vasoplegia.

METHODS: We searched PubMed, Embase, and Cochrane Library for RCTs comparing non-adrenergic vasopressors with adrenergic vasopressors alone or placebo in critically ill or perioperative patients. Each eligible study was categorized into septic shock, cardiac surgery, or non-cardiac surgery. Non-adrenergic vasopressors included vasopressin, terlipressin, selepressin, angiotensin II, methylene blue, and hydroxocobalamin. The primary outcome was mortality at longest follow-up. We conducted a random-effects meta-analysis. We registered the protocol in PROSPERO International Prospective Register of Systematic Reviews (CRD42024505039).

RESULTS: Among 51 eligible RCTs totaling 5715 patients, the predominant population was septic shock in 30 studies, cardiac surgery in 11 studies, and non-cardiac surgery in 10 studies. Cochrane risk-of-bias tool for randomized trials version 2 identified 17 studies as low risk of bias. In septic shock, mortality was significantly lower in the non-adrenergic group (960/2232 [43%] vs. 898/1890 [48%]; risk ratio [RR], 0.92; 95% confidence interval [95% CI], 0.86-0.97; P = 0.03; I2 = 0%), with none of the individual non-adrenergic vasopressors showing significant survival benefits. No significant mortality difference was observed in patients undergoing cardiac surgery (34/410 [8.3%] vs. 47/412 [11%]; RR, 0.82; 95% CI, 0.55-1.22; P = 0.32; I2 = 12%) or those undergoing non-cardiac surgery (9/388 [2.3%] vs. 18/383 [4.7%]; RR, 0.66; 95% CI, 0.31-1.41; P = 0.28; I2 = 0%).

CONCLUSIONS: Administration of non-adrenergic vasopressors was significantly associated with reduced mortality in patients with septic shock. However, no single agent achieved statistical significance in separate analyses. Although the pooled effects of non-adrenergic vasopressors on survival did not reach statistical significance in patients undergoing cardiac or non-cardiac surgery, the confidence intervals included the possibility of both no effect and a clinically important benefit from non-adrenergic agents. These findings justify the conduct of further RCTs comparing non-adrenergic vasopressors to usual care based on noradrenaline alone.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Kotani Y, Belletti A, D'Amico F, et al. Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials. Crit Care. 2024. PMID: 39736782. doi:10.1186/s13054-024-05212-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。